Insulins: Past, present, and future

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 1, 2012, Pages 1-24

  Borgoño, Carla A ^a   Zinman, Bernard ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Injectable insulin; Insulin analogues; Pharmacokinetics

Indexed keywords

ANTIDIABETIC AGENT; BIOD ADJUSTABLE BASAL; BIOD SMART BASAL; FT 105; GLUCOSE; HUMALOG MIX 50 50; HUMALOG MIX 75 25; HUMAN INSULIN; IDEG; INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN LISPRO PROTAMINE; INSULIN PH20; ISOPHANE INSULIN; LINJETA; LY 2605541; LY 2963016; NOVOLIN 50 50; NOVOLIN 70 30; NOVOLIN GE TORONTO; NOVOLOG MIX 30; RECOMBINANT HUMAN INSULIN; RECOMBINANT HYALURONIDASE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; BLOOD GLUCOSE MONITORING; BREAST CANCER; CANCER RISK; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN METABOLISM; INSULIN RELEASE; INSULIN TREATMENT; MATERNAL TREATMENT; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SATISFACTION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; PRIORITY JOURNAL; PROTEIN ENGINEERING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

ANIMALIA;

EID: 84860624484     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2012.03.002     Document Type: Review

References (181)

1. Von Mering J., Minkowski O. Diabetes mellitus nach pankreasexstirpation. Archiv für experimentelle Pathologie und Pharmakologie 1890, 26:371-387. [in German].
2. Opie E.L. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med 1901, 5:527-540.
3. Ssobolew L.W. Zur normalen und pathologischen Morphologie der inneren Secretion der Bauchspeicheldrüse. Archiv für pathologische und anatomie und physiologie und für klinische medizine 1902, 168:91-128. [in German].
4. Sharpey-Schäfer E.A. An introduction to the Study of the endocrine glands and internal secretions: lane medical lectures, 1913 1914, Stanford University, Palo Alto (CA).
5. Zuelzer G. Ueber versuche einer specifischen fermenttherapie des diabetes. Zeitschrift für experimentelle pathologie und therapie 1908, 5:307-318. [in German].
6. Scott E.L. On the influence of intravenous injections of an extract of the pancreas on experimental pancreatic diabetes. Am J Physiol 1912, 29:306-310.
7. Kleiner I.S. The action of intravenous injections of pancreas emulsions in experimental diabetes. J Biol Chem 1919, 40:153-170.
8. Murlin J.R., Kramer B. The influence of pancreatic and duodenal extracts on the glycosuria and the respiratory metabolism of depancreatized dogs. J Biol Chem 1913, 15:365-383.
9. Paulesco N.C. Action de l'extrait pancréatique injecté dans le sang, chez un animal diabétique. Comptes rendus des séances de la Société de biologie 1921, 85:555-559. [in French].
10. Barron M. The relation of the islets of Langerhans to diabetes with special reference to cases of pancreatic lithiasis. Surg Gynecol Obstet 1920, 31:437-448.
11. Banting F.G. The history of insulin. Edinb Med J 1929, 36:1-18.
12. Banting F.G., Best C.H. The internal secretion of the pancreas. J Lab Clin Med 1922, 7:251-266.
13. Banting F.G., Best C.H., Collip J.B., et al. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922, 12:141-146.
14. Hagedorn H.C., Jensen B.N., Krarup N.B., et al. Protamine insulinate. JAMA 1936, 106:177-180.
15. Scott D.A., Fisher A.M. Studies on insulin with protamine. J Pharmacol Exp Therapeut 1936, 58:78-92.
16. Himsworth H.P. Protamine insulin and zinc protamine insulin. Br Med J 1937, 1:541-546.
17. Krayenbuhl C., Rosenberg T. Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab 1946, 1:60-73.
18. Hallas-Moller K. The lente insulins. Diabetes 1956, 5:7-14.
19. Oakley W., Hill D., Oakley N. Combined use of regular and crystalline protamine (NPH) insulins in the treatment of severe diabetes. Diabetes 1966, 15:219-222.
20. Sanger F. Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes. Science 1959, 129:1340-1344.
21. Markussen J., Damgaard U., Jorgensen K.H., et al. Human monocomponent insulin. Chemistry and characteristics. Acta Med Scand Suppl 1983, 671:99-105.
22. Meienhofer J., Schnabel E., Bremer H., et al. Z Naturforsch B 1963, 18:1120-1121. [in German].
23. Kung Y.T., Du Y.C., Huang W.T., et al. Total synthesis of crystalline insulin. Sci Sin 1966, 15:544-561.
24. Katsoyannis P.G., Tometsko A., Zalut C. Insulin peptides. XII. Human insulin generation by combination of synthetic A and B chains. J Am Chem Soc 1966, 88:166-167.
25. Morihara K., Oka T., Tsuzuki H. Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin. Nature 1979, 280:412-413.
26. Markussen J., Damgaard U., Pingel M., et al. Human insulin (Novo): chemistry and characteristics. Diabetes Care 1983, 6(Suppl 1):4-8.
27. Teuscher A. Schweiz Med Wochenschr 1979, 109:743-747. [in German].
28. Keen H., Glynne A., Pickup J.C., et al. Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet 1980, 2:398-401.
29. Owens D.R., Zinman B., Bolli G.B. Insulins today and beyond. Lancet 2001, 358:739-746.
30. Hirsch I.B. Insulin analogues. N Engl J Med 2005, 352:174-183.
31. Owens D.R., Zinman B., Bolli G. Alternative routes of insulin delivery. Diabet Med 2003, 20:886-898.
32. Pickup J.C., Keen H., Parsons J.A., et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1978, 1:204-207.
33. Pickup J., Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002, 25:593-598.
34. Waldron-Lynch F., Herold K.C. Continuous glucose monitoring: long live the revolution!. Nat Clin Pract Endocrinol Metab 2009, 5:82-83.
35. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011, 7:385-395.
36. Rojdmark S., Bloom G., Chou M.C., et al. Hepatic extraction of exogenous insulin and glucagon in the dog. Endocrinology 1978, 102:806-813.
37. Zinman B. The physiologic replacement of insulin. An elusive goal. N Engl J Med 1989, 321:363-370.
38. Wild S., Roglic G., Green A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
39. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
40. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.
41. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
42. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
43. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342:381-389.
44. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
45. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003, 348:2294-2303.
46. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
47. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
48. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
49. Standl E., Balletshofer B., Dahl B., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996, 39:1540-1545.
50. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997, 46:271-286.
51. Binder C., Lauritzen T., Faber O., et al. Insulin pharmacokinetics. Diabetes Care 1984, 7:188-199.
52. Kang S., Brange J., Burch A., et al. Subcutaneous insulin absorption explained by insulin's physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care 1991, 14:942-948.
53. Heinemann L., Richter B. Clinical pharmacology of human insulin. Diabetes Care 1993, 16(Suppl 3):90-100.
54. Cryer P.E. Banting lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994, 43:1378-1389.
55. Starke A.A., Heinemann L., Hohmann A., et al. The action profiles of human NPH insulin preparations. Diabet Med 1989, 6:239-244.
56. Peterson G.E. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin 2006, 22:2613-2619.
57. Bolli G.B. The pharmacokinetic basis of insulin therapy in diabetes mellitus. Diabetes Res Clin Pract 1989, 6:S3-S15. [discussion: S15-6].
58. Lepore M., Pampanelli S., Fanelli C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000, 49:2142-2148.
59. Jehle P.M., Micheler C., Jehle D.R., et al. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens. Lancet 1999, 354:1604-1607.
60. Mooradian A.D., Bernbaum M., Albert S.G. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006, 145:125-134.
61. Holleman F., Hoekstra J.B. Insulin lispro. N Engl J Med 1997, 337:176-183.
62. Brems D.N., Alter L.A., Beckage M.J., et al. Altering the association properties of insulin by amino acid replacement. Protein Eng 1992, 5:527-533.
63. Brange J., Owens D.R., Kang S., et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990, 13:923-954.
64. Mudaliar S.R., Lindberg F.A., Joyce M., et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999, 22:1501-1506.
65. Barlocco D. Insulin glulisine. Aventis pharma. Curr Opin Investig Drugs 2003, 4:1240-1244.
66. Becker R.H., Frick A.D. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008, 47:7-20.
67. Danne T., Becker R.H., Heise T., et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005, 28:2100-2105.
68. Homko C., Deluzio A., Jimenez C., et al. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 2003, 26:2027-2031.
69. Becker R.H., Frick A.D., Burger F., et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005, 113:435-443.
70. ter Braak E.W., Woodworth J.R., Bianchi R., et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996, 19:1437-1440.
71. Anderson J.H., Brunelle R.L., Koivisto V.A., et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997, 46:265-270.
72. Del Sindaco P., Ciofetta M., Lalli C., et al. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998, 15:592-600.
73. Brange J., Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999, 35:307-335.
74. Brunelle B.L., Llewelyn J., Anderson J.H., et al. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998, 21:1726-1731.
75. Home P.D., Lindholm A., Hylleberg B., et al. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 1998, 21:1904-1909.
76. Hermansen K., Fontaine P., Kukolja K.K., et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004, 47:622-629.
77. Raskin P., Guthrie R.A., Leiter L., et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000, 23:583-588.
78. Gough S.C. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007, 77:1-15.
79. Plank J., Siebenhofer A., Berghold A., et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005, 165:1337-1344.
80. Rave K., Klein O., Frick A.D., et al. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006, 29:1812-1817.
81. Siebenhofer A., Plank J., Berghold A., et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006, 2. CD003287.
82. Kotsanos J.G., Vignati L., Huster W., et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro. Assessing benefits of a new diabetes therapy. Diabetes Care 1997, 20:948-958.
83. Kamoi K., Miyakoshi M., Maruyama R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITR-QOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004, 64:19-25.
84. Grey M., Boland E.A., Tamborlane W.V. Use of lispro insulin and quality of life in adolescents on intensive therapy. Diabetes Educ 1999, 25:934-941.
85. Bott U., Ebrahim S., Hirschberger S., et al. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med 2003, 20:626-634.
86. Miles H.L., Acerini C.L. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs 2008, 10:163-176.
87. Bolli G.B., Di Marchi R.D., Park G.D., et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999, 42:1151-1167.
88. Bolli G.B., Owens D.R. Insulin glargine. Lancet 2000, 356:443-445.
89. Buse J. Insulin glargine (HOE901): first responsibilities: understanding the data and ensuring safety. Diabetes Care 2000, 23:576-578.
90. Barlocco D. Insulin detemir. Novo Nordisk. Curr Opin Investig Drugs 2003, 4:449-454.
91. Havelund S., Plum A., Ribel U., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004, 21:1498-1504.
92. Kurtzhals P., Havelund S., Jonassen I., et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995, 312(Pt 3):725-731.
93. Markussen J., Havelund S., Kurtzhals P., et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996, 39:281-288.
94. Heise T., Pieber T.R. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007, 9:648-659.
95. Plank J., Bodenlenz M., Sinner F., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005, 28:1107-1112.
96. Heinemann L., Linkeschova R., Rave K., et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000, 23:644-649.
97. Klein O., Lynge J., Endahl L., et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007, 9:290-299.
98. Heinemann L., Sinha K., Weyer C., et al. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 1999, 16:332-338.
99. Heise T., Nosek L., Rønn B.B., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004, 53:1614-1620.
100. Owens D.R., Coates P.A., Luzio S.D., et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23:813-819.
101. Ratner R.E., Hirsch I.B., Neifing J.L., et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000, 23:639-643.
102. Riddle M.C., Rosenstock J., Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26:3080-3086.
103. Home P., Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 2006, 7:325-343.
104. Kølendorf K., Ross G.P., Pavlic-Renar I., et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 2006, 23:729-735.
105. Philis-Tsimikas A., Charpentier G., Clauson P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006, 28:1569-1581.
106. Robertson K.J., Schoenle E., Gucev Z., et al. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007, 24:27-34.
107. Bartley P.C., Bogoev M., Larsen J., et al. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008, 25:442-449.
108. Blonde L., Merilainen M., Karwe V., et al. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab 2009, 11:623-631.
109. Garg S., Moser E., Dain M.P., et al. Clinical experience with insulin glargine in type 1 diabetes. Diabetes Technol Ther 2010, 12:835-846.
110. Horvath K., Jeitler K., Berghold A., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, 2. CD005613.
111. Abrahamson M.J. Basal insulins: pharmacological properties and patient perspectives. Prim Care Diabetes 2010, 4(Suppl 1):S19-S23.
112. Murphy N.P., Keane S.M., Ong K.K., et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26:799-804.
113. Ashwell S.G., Amiel S.A., Bilous R.W., et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006, 23:285-292.
114. Raslová K., Bogoev M., Raz I., et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004, 66:193-201.
115. Hermansen K., Davies M., Derezinski T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006, 29:1269-1274.
116. Rosenstock J., Davies M., Home P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008, 51:408-416.
117. Swinnen S.G., Dain M.P., Aronson R., et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010, 33:1176-1178.
118. DeWitt D.E., Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003, 289:2254-2264.
119. Yamada S., Watanabe M., Kitaoka A., et al. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. Intern Med 2007, 46:1513-1517.
120. Roach P., Yue L., Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999, 22:1258-1261.
121. Koivisto V.A., Tuominen J.A., Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999, 22:459-462.
122. Malone J.K., Woodworth J.R., Arora V., et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000, 22:222-230.
123. Kilo C., Mezitis N., Jain R., et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabet Complications 2003, 17:307-313.
124. Mortensen H., Kocova M., Teng L.Y., et al. Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes 2006, 7:4-10.
125. Boehm B.O., Home P.D., Behrend C., et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med 2002, 19:393-399.
126. Coscelli C., Calabrese G., Fedele D., et al. Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures. Diabetes Care 1992, 15:1628-1630.
127. Slieker L.J., Brooke G.S., DiMarchi R.D., et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997, 40(Suppl 2):S54-S61.
128. Werner H., Weinstein D., Bentov I. Similarities and differences between insulin and IGF-I: structures, receptors, and signalling pathways. Arch Physiol Biochem 2008, 114:17-22.
129. Yehezkel E., Weinstein D., Simon M., et al. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 2010, 53:2667-2675.
130. Gerstein H.C. Does insulin therapy promote, reduce, or have a neutral effect on cancers?. JAMA 2010, 303:446-447.
131. Hansen B.F., Danielsen G.M., Drejer K., et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996, 315(Pt 1):271-279.
132. Kurtzhals P., Schäffer L., Sørensen A., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49:999-1005.
133. Sciacca L., Cassarino M.F., Genua M., et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 2010, 53:1743-1753.
134. Shukla A., Grisouard J., Ehemann V., et al. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 2009, 16:429-441.
135. Mayer D., Chantelau E. Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 2010, 116:73-78.
136. Staiger K., Hennige A.M., Staiger H., et al. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 2007, 39:65-67.
137. Stammberger I., Bube A., Durchfeld-Meyer B., et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002, 21:171-179.
138. Jonasson J.M., Ljung R., Talbäck M., et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
139. Colhoun H.M. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
140. Hemkens L.G., Grouven U., Bender R., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-1744.
141. Mannucci E., Monami M., Balzi D., et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010, 33:1997-2003.
142. Pocock S.J., Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet 2009, 374:511-513.
143. Hernandez-Diaz S., Adami H.O. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 2010, 53:802-808.
144. Rosenstock J., Fonseca V., McGill J.B., et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009, 52:1971-1973.
145. Home P.D., Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009, 52:2499-2506.
146. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
147. Suissa S., Azoulay L., Dell'Aniello S., et al. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 2011, 54:2254-2262.
148. Dejgaard A., Lynggaard H., Rastam J., et al. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009, 52:2507-2512.
149. Giovannucci E., Harlan D.M., Archer M.C., et al. Diabetes and cancer: a consensus report. Diabetes Care 2010, 33:1674-1685.
150. Lapolla A., Di Cianni G., Bruttomesso D., et al. Use of insulin detemir in pregnancy: a report on 10 type 1 diabetic women. Diabet Med 2009, 26:1181-1182.
151. Mecacci F., Carignani L., Cioni R., et al. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol 2003, 111:19-24.
152. Jovanovic L., Ilic S., Pettitt D.J., et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999, 22:1422-1427.
153. Persson B., Swahn M.L., Hjertberg R., et al. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 2002, 58:115-121.
154. Mathiesen E.R., Kinsley B., Amiel S.A., et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007, 30:771-776.
155. Singh S.R., Ahmad F., Lal A., et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 180:385-397.
156. Graves D.E., White J.C., Kirk J.K. The use of insulin glargine with gestational diabetes mellitus. Diabetes Care 2006, 29:471-472.
157. Price N., Bartlett C., Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007, 114:453-457.
158. Gallen I.W., Jaap A., Roland J.M., et al. Survey of glargine use in 115 pregnant women with type 1 diabetes. Diabet Med 2008, 25:165-169.
159. Di Cianni G., Torlone E., Lencioni C., et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabet Med 2008, 25:993-996.
160. Fang Y.M., MacKeen D., Egan J.F., et al. Insulin glargine compared with neutral protamine Hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med 2009, 22:249-253.
161. Torlone E., Di Cianni G., Mannino D., et al. Insulin analogs and pregnancy: an update. Acta Diabetol 2009, 46:163-172.
162. Vaughn D.E., Yocum R.C., Muchmore D.B., et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009, 11:345-352.
163. Muchmore D.B., Vaughn D.E. Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol 2010, 4:419-428.
164. Steiner S., Hompesch M., Pohl R., et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008, 51:1602-1606.
165. Hompesch M., McManus L., Pohl R., et al. Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin. J Diabetes Sci Technol 2008, 2:568-571.
166. Heinemann L., Nosek L., Flacke F., et al. U-100, pH-Neutral formulation of VIAject((R)): faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 2012, 14(3):222-227. [Epub 2011 Nov 13]. 10.1111/j.1463-1326.2011.01516.x.
167. Owens D.R. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011, 13(Suppl 1):S5-S14.
168. Simon A.C., DeVries J.H. The future of basal insulin supplementation. Diabetes Technol Ther 2011, 13(Suppl 1):S103-S108.
169. Chacra A.R., Kipnes M., Ilag L.L., et al. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. Diabet Med 2010, 27:563-569.
170. Fogelfeld L., Dharmalingam M., Robling K., et al. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabet Med 2010, 27:181-188.
171. Hinds K.D., Kim S.W. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 2002, 54:505-530.
172. Chan Y.P., Meyrueix R., Kravtzoff R., et al. Review on Medusa: a polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv 2007, 4:441-451.
173. Jonassen I., Havelund S., Ribel U., et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multihexamer formation. Diabetes 2010, 59:A11. [abstract].
174. Birkeland K.I., Home P.D., Wendisch U., et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34:661-665.
175. Heise T., Tack C.J., Cuddihy R., et al. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011, 34:669-674.
176. Zinman B., Fulcher G., Rao P.V., et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 2011, 377:924-931.
177. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008, 32:S1-S201.
178. American Diabetes Association Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
179. Handelsman Y., Mechanick J.I., Blonde L., et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011, 17(Suppl 2):1-53.
180. Rydén L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28:88-136.
181. International Diabetes Federation Guideline for the management of post-meal blood glucose. Diabetes Voice 2007, 52:9-11.